Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Relapse Rates With Surgery Alone in Human Papillomavirus-Related Intermediate- and High-Risk Group Oropharynx Squamous Cell Cancer: A Multi-Institutional Review.

Routman DM, Funk RK, Tangsriwong K, Lin A, Keeney MG, García JJ, Zarka MA, Lewis JT, Stoddard DG, Moore EJ, Day CN, Zhai Q, Price KA, Lukens JN, Swisher-McClure S, Weinstein GS, O'Malley BW Jr, Foote RL, Ma DJ.

Int J Radiat Oncol Biol Phys. 2017 Jun 28. pii: S0360-3016(17)33519-8. doi: 10.1016/j.ijrobp.2017.06.2453. [Epub ahead of print]

PMID:
28847412
2.

Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation.

Alsidawi S, Price KA, Chintakuntlawar AV, Westin GF, Garcia JJ, Ma DJ, Okuno SH.

Oral Oncol. 2017 Sep;72:104-109. doi: 10.1016/j.oraloncology.2017.07.010. Epub 2017 Jul 17.

PMID:
28797445
3.

Concurrent Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx in a Married Couple.

Brobst TD, García JJ, Price KA, Gao G, Smith DI, Price DL.

Case Rep Otolaryngol. 2016;2016:8481235. doi: 10.1155/2016/8481235. Epub 2016 Jun 22.

4.

High-grade transformation of acinic cell carcinoma: an inadequately treated entity?

Chintakuntlawar AV, Shon W, Erickson-Johnson M, Bilodeau E, Jenkins SM, Davidson JA, Keeney MG, Rivera M, Price DL, Moore EJ, Olsen KD, Kasperbauer JL, Foote RL, Price KA, García JJ.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):542-549.e1. doi: 10.1016/j.oooo.2016.01.011. Epub 2016 Jan 21.

PMID:
27017401
5.

Risk factors for locoregional relapse after transoral robotic surgery for human papillomavirus-related oropharyngeal squamous cell carcinoma.

Funk RK, Moore EJ, García JJ, Harmsen WS, Stoddard DG, Vencio EF, Foote RL, Price KA, Ma DJ.

Head Neck. 2016 Apr;38 Suppl 1:E1674-9. doi: 10.1002/hed.24298. Epub 2015 Dec 15.

PMID:
26667985
6.
7.

Symptom burden and integrative medicine in cancer survivorship.

Cutshall SM, Cha SS, Ness SM, Stan DL, Christensen SA, Bhagra A, Price KA, Thompson CA, Hashmi SK, Chon TY, McCray TJ, Sood A, Bauer BA, Ruddy KJ.

Support Care Cancer. 2015 Oct;23(10):2989-94. doi: 10.1007/s00520-015-2666-0. Epub 2015 Feb 28.

8.

Nonpharmacologic approach to fatigue in patients with cancer.

Pachman DR, Price KA, Carey EC.

Cancer J. 2014 Sep-Oct;20(5):313-8. doi: 10.1097/PPO.0000000000000064. Review.

PMID:
25299140
9.

Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder.

Vaa B, Kohli M, Price KA, Swetz KM.

BMJ Case Rep. 2014 Jun 11;2014. pii: bcr2013200137. doi: 10.1136/bcr-2013-200137.

10.

Acinic cell carcinoma of the salivary gland with metastatic spread to the pancreas.

Geiger JL, García JJ, Price KA.

Case Rep Oncol. 2014 Mar 13;7(1):195-8. doi: 10.1159/000360395. eCollection 2014 Jan.

11.

Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.

Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, Olsen KD, Kasperbauer JL, Price DL, Garces YI, Ma DJ, Neben-Wittich MA, Molina JR, Garcia JJ, Price KA.

Oral Oncol. 2014 Apr;50(4):311-8. doi: 10.1016/j.oraloncology.2014.01.001. Epub 2014 Jan 24.

PMID:
24467937
12.

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA.

J Thorac Oncol. 2013 Aug;8(8):1084-90. doi: 10.1097/JTO.0b013e31829923ec.

13.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK.

Cancer Chemother Pharmacol. 2013 Aug;72(2):453-61. doi: 10.1007/s00280-013-2219-5. Epub 2013 Jun 28.

14.

Oropharyngeal cancer biology and treatment: insights from messenger RNA sequence analysis and transoral robotic surgery.

Foote RL, Garces YI, Neben Wittich MA, Ma DJ, Park SS, Molina JR, Okuno SH, Price KA, Schild SE, Patel SH.

Mayo Clin Proc. 2012 Nov;87(11):1132; author reply 1132-3. doi: 10.1016/j.mayocp.2012.08.007. No abstract available.

15.

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA.

J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f.

16.

Current treatment options for metastatic head and neck cancer.

Price KA, Cohen EE.

Curr Treat Options Oncol. 2012 Mar;13(1):35-46. doi: 10.1007/s11864-011-0176-y. Review.

PMID:
22252884
17.

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA.

J Thorac Oncol. 2010 Oct;5(10):1623-9. doi: 10.1097/JTO.0b013e3181ec1531.

18.

Hydration in cancer patients.

Price KA.

Curr Opin Support Palliat Care. 2010 Dec;4(4):276-80. doi: 10.1097/SPC.0b013e32833e48d1. Review.

PMID:
20693908
19.

Advances in treatment for non-small cell lung cancer.

Price KA, Jett JR.

Int J Tuberc Lung Dis. 2010 Jul;14(7):792-4. No abstract available.

PMID:
20550759
20.

Chemoradiation for unresectable stage III non-small cell lung cancer.

Price KA, Azzoli CG, Gaspar LE.

Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):204-9. doi: 10.1053/j.semtcvs.2008.09.007. Review.

PMID:
19038729

Supplemental Content

Loading ...
Support Center